Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cureus|October 9, 2023
Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast CancerMaher Alhaja, Sherry Chen, Alan C Chin, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|February 5, 2019
A Brain-Robot Interaction System by Fusing Human and Machine IntelligenceXiaoqian Mao, Wei Li, Chengwei Lei, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 10, 2026
A lifespan staging model of basal forebrain cholinergic vulnerabilityHayley R C Shanks, Sherry Chen, Kate M Onuska, et al.
Journal of Cutaneous Medicine and Surgery|January 28, 2022
Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)David Rosmarin, Marta Casillas, Sherry Chen, et al.
Public Health Reports (Washington, D.C. : 1974)|May 12, 2016
"Know Hepatitis B:" A Multilingual Communications Campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific IslandersCynthia Jorgensen, Sherry Chen, C Amanda Carnes, et al.
Clinical Genitourinary Cancer|July 17, 2026
Patient-Reported Outcome Design and Analysis in Randomized Controlled Trials of Renal Cell Carcinoma: A Systematic ReviewDavid Chen, Sherry Chen, Daisy Sun, et al.
Journal of Cutaneous Medicine and Surgery|March 31, 2022
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 StudyDavid Rosmarin, Scott Fretzin, Lindsay Strowd, et al.
Dermatology and Therapy|July 18, 2021
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7Jacob P Thyssen, Timo Buhl, Pablo Fernández-Peñas, et al.
The British Journal of Dermatology|February 10, 2023
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3Kristian Reich, Eric Simpson, Andreas Wollenberg, et al.
Dermatology and Therapy|April 26, 2021
Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 StudiesTimo Buhl, David Rosmarin, Esther Serra-Baldrich, et al.
Pageof 2